# **Reduced function of endothelial prostacyclin in human omental resistance arteries in pre-eclampsia**

Yoshikatsu Suzuki \*†, Tomonori Hattori †, Junko Kajikuri †, Tamao Yamamoto \*†, Kaoru Suzumori \* and Takeo Itoh †

*Departments of \* Obstetrics and Gynecology and † Cellular and Molecular Pharmacology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan*

> **It remains unclear in pre-eclampsia whether or not a functional change occurs in the role played by prostacyclin in endothelium-dependent relaxation in resistance arteries. We examined this using human omental resistance arteries (obtained from pre-eclamptic or normotensive pregnant** women) in the presence of  $N^G$ -nitro-L-arginine (L-NNA, an inhibitor of nitric oxide synthase). In endothelium-intact strips from both groups, 9,11-epithio-11,12-methano-thromboxane A<sub>2</sub> (STA<sub>2</sub>, **a thromboxane A2 mimetic) produced a contraction. Diclofenac (an inhibitor of cyclooxygenase) enhanced the STA2 contraction only in the normotensive pregnant group (1.4 times control,**  $P < 0.01$ ). In the presence of STA<sub>2</sub>, bradykinin  $(0.1 \mu M)$  produced an endothelium-dependent **relaxation in both groups, the relaxation being significantly smaller for the pre-eclamptic group (***P* **< 0.002). Diclofenac significantly attenuated the bradykinin-induced relaxation only for the normotensive pregnant group (31 % inhibition,** *P* **< 0.001). The bradykinin-induced membrane hyperpolarization consisted of diclofenac-sensitive and -insensitive components. The former, but** not the latter, was significantly smaller in pre-eclampsia  $(-4.3 \text{ v}s. -2.6 \text{ mV}, P < 0.05)$ . The **concentrations of 6-keto-PGF1**<sup>a</sup> **(a stable metabolite of prostacyclin) in these arteries were significantly lower in pre-eclampsia in both the absence and presence of bradykinin (about 0.2–0.4 times the normotensive pregnant value in each case,** *P* **< 0.01). By contrast, both the** relaxation and the membrane hyperpolarization in response to beraprost (10 nm, a stable analogue **of prostacyclin) were similar between the two groups. We conclude that, in pre-eclampsia, a reduced part is played by prostaglandins in the endothelium-dependent relaxation seen in resistance arteries and that this may be due to a reduced production of prostacyclin by the endothelium.**

> (Received 11 April 2002; accepted after revision 2 September 2002; first published online 27 September 2002) **Corresponding author** Y. Suzuki: Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Nagoya City University, Mizuho-ku, Nagoya 467-8601, Japan. Email: og.yo@med.nagoya-cu.ac.jp

Vascular endothelial cells release vasorelaxing factors, such as nitric oxide (NO), prostacyclin and endotheliumderived hyperpolarizing factor (EDHF), and these play an important role in the regulation of vascular tone, vascular permeability and blood coagulation, thus helping to maintain circulatory homeostasis (Vallance *et al.* 1989; Moncada *et al.* 1991; Kuriyama *et al.* 1998). Pre-eclampsia is a pregnancy-specific syndrome characterized by marked increases in peripheral vascular resistance and vascular permeability together with a disturbance of blood coagulation (Lenfant *et al.* 1990; Cines *et al.* 1998; Cunningham, 2001). Among the endothelium-derived relaxing factors, an abnormality in the role played by endothelium-derived NO has been suggested in resistance arteries in pre-eclampsia (Poston *et al.* 1995; Sladek *et al.* 1997; Suzuki *et al.* 2000), while the function of EDHF seems to be preserved in some human resistance arteries in this condition (Pascoal *et al.* 1998; Suzuki *et al.* 2000).

Prostacyclin is synthesized in vascular endothelium and is known to be a potent vasodilator as well as a powerful inhibitor of platelet aggregation (Moncada *et al.* 1976). During pregnancy, the synthesis of 6-keto-PGF $_{1\alpha}$  (a stable metabolite of prostacyclin) has been found to be increased in fetoplacental and umbilical tissues and is thought to play an important role in the regulation of not only the maternal but also the fetal blood circulation in pregnancy (Remuzzi *et al.* 1979). In pre-eclampsia, the urinary and blood concentrations of 6-keto-PGF $_{1\alpha}$  are significantly decreased by comparison with those in normotensive pregnant women (Goodman *et al.* 1982; Fitzgerald *et al.* 1987). Furthermore, the production of placental 6-keto- $PGF_{1\alpha}$  in pre-eclampsia is less than one-half that seen in normal pregnant women (Walsh, 1985), suggesting that in pre-eclampsia, a reduced function of endothelium-derived prostacyclin occurs in vascular beds. However, contrary evidence has also been reported in that, in pre-eclampsia,

the endothelium-dependent relaxation mediated by prostaglandins (PGs) is not modified in the arteries of subcutaneous fat, although the endothelium-dependent relaxation mediated by NO is reduced (compared with that in normotensive pregnant women; Knock & Poston, 1996). Thus, it remains to be clarified whether or not the role played by endothelium-derived prostacyclin is changed in resistance arteries in pre-eclampsia. Furthermore, if this happens, the underlying mechanism has not yet been clarified.

To examine this issue, we first investigated the effect of bradykinin (to stimulate endothelial release of PGs and EDHF) on the contraction induced by the stable thromboxane  $A_2$  analogue, 9,11-epithio-11,12-methanothromboxane A<sub>2</sub> (STA<sub>2</sub>; Kanmura *et al.* 1987), in the presence of the NO synthase inhibitor,  $N<sup>G</sup>$ -nitro-L-arginine (L-NNA, to prevent production of endothelial NO), in endotheliumintact strips from omental resistance arteries from normotensive pregnant and pre-eclamptic women. Next, we examined the effect of bradykinin on the smooth muscle cell membrane potential (to look for a change in the effect of PGs on the membrane potential) in endothelium-intact strips treated with L-NNA. Finally, we measured the production of 6-keto-PGF<sub>1 $\alpha$ </sub> in the absence and presence of bradykinin in L-NNA-treated, endothelium-intact strips from both groups of women.

## **METHODS**

#### **Preparations**

The procedures used in this study conformed to the standards set by the Declaration of Helsinki and were approved by the institutional review boards of Nagoya City University Medical School. Written informed consent was obtained from all patients. Muscle strips with intact endothelium were cut from omental resistance arteries (outer diameter, 0.1–0.3 mm) obtained from 25 normotensive pregnant and 13 pre-eclamptic women at Caesarean section. Pre-eclampsia was diagnosed according to the criteria laid down by the National High Blood Pressure Education Program (Lenfant *et al*. 1990; Table 1). Women with a history of smoking or a history complicated by certain diseases (diabetes mellitus, renal disease, collagen disorders or infections) were excluded from both groups since the function of the endothelium is known to be changed by smoking and by these diseases. Two out of 13 pre-eclamptic patients took oral hydralazine (to decrease their blood pressure) after the onset of pre-eclampsia. The other 11 pre-eclamptic women received no medication except anaesthetic agents (for the surgical operation). No medication (except anaesthetic) was received by the normotensive pregnant women. Among the normotensive pregnant women, two received 2.5 ml of 0.5 % bupivacaine to induce spinal anaesthesia while the other 23 received ketamine (5 mg  $kg^{-1}$ , given intramuscularly) for general anaesthesia. In pre-eclamptic patients, thiopentone (5 mg  $kg^{-1}$ , given intravenously) was used for general anaesthesia (2 patients) and 2.5 ml of 0.5% bupivacaine for spinal anaesthesia (11 patients).

The tissue specimens ( $\sim$ 4 cm<sup>2</sup>) were immediately placed in Krebs solution and transported to the laboratory. Omental artery segments (3 cm in length) were excised and the tissues were

prepared as follows in Krebs solution at room temperature. The connective tissue was carefully removed under a binocular microscope and the artery was cut along its long axis with small scissors so as not to damage the endothelium. Small circularly cut muscle strips with intact endothelium (0.1–0.3 mm in width, 0.05–0.08 mm in thickness, 0.3–0.4 mm in length) were prepared, as described previously (Itoh *et al.* 1992; Yamakawa *et al.* 1997; Suzuki *et al.* 2000). The usefulness of this preparation in investigations of endothelium-dependent responses in small resistance arteries has been reported previously in studies involving membrane potential changes (Yamakawa *et al.* 1997), the production of prostanoids (Suzuki *et al.* 1991) or measurement of isometric tension (Suzuki *et al.* 2000). In some experiments, the endothelium was removed using a small razor blade, as described previously (Itoh *et al.* 1992; Suzuki *et al.* 2000) and the lack of endothelial function was pharmacologically verified by the absence of a bradykinin-induced relaxation on the noradrenaline (3  $\mu$ M)-induced contraction. When an endotheliumintact strip was used, the strip was pretreated with the NO synthase inhibitor, L-NNA, for 90 min before the start of the experiment and L-NNA was then present throughout. The concentration of L-NNA used was 0.3 mM, as in a previous report (Kakuyama *et al.* 1998). Guanethidine (5  $\mu$ m, to prevent effects due to release of sympathetic transmitters; Mishima *et al.* 1984) was present in all the solutions used in the present experiments.

#### **Recording of mechanical responses**

An endothelium-intact muscle strip was placed in a chamber with a capacity of 0.3 ml and superfused with Krebs solution at a flow rate of about 2 ml  $min^{-1}$ . Both ends of the preparation were fixed and isometric tension was recorded using a strain-gauge transducer (AE801; SensoNor a.s., Horten, Norway), as described previously (Suzuki *et al*. 2000). A resting tension of 2–3 mg was applied so as to obtain a maximum contraction in 80 mm  $K^+$ . Each preparation was allowed to equilibrate for 2 h before the start of the experiments. The length, width, thickness and the crosssectional area of the preparation were measured with the aid of an inverted microscope at  $\times$ 250 magnification (using a calibrated scale). The transverse cross-sectional area was calculated assuming a rectangular cross-section, as described previously (Itoh *et al.* 1992; Suzuki *et al*. 2000). Tension measurements were then expressed in kilonewtons per metre squared (kN  $m^{-2}$ ).

In previous studies, we found that  $STA<sub>2</sub>$  (a stable analogue of thromboxane  $A_2$ , 0.03–10 nM) produced a concentration-dependent contraction in both groups of women, the sensitivity to  $STA<sub>2</sub>$  of endothelium-intact strips being higher for pre-eclamptic women than for normotensive pregnant women (Suzuki *et al*. 2000). For this reason, unless otherwise stated, the concentration of  $STA<sub>2</sub>$ used was 3 nM in strips from normotensive pregnant women and 1 nM in strips from pre-eclamptic women; these concentrations were used to obtain contractions of approximately equal amplitude (Table 2). When oscillations in tension occurred in the presence of  $STA<sub>2</sub>$ , the level was taken to be at the mid-point of the amplitude of the oscillations. When the effect of the cyclooxygenase inhibitor, diclofenac, was to be observed, the concentration used was  $3 \mu$ M so as to obtain its selective action, as described previously (Yamashita *et al.* 1999). Strips were pretreated with diclofenac for 60 min after recording a reproducible control response and diclofenac was then present throughout the experiment.

Endothelium-dependent relaxation was induced by an application of bradykinin  $(0.1 \mu M)$  during the contraction induced by STA<sub>2</sub>. For this set of experiments, the preparations were first contracted with  $STA<sub>2</sub>$  and, after a steady-state contraction had been attained, bradykinin was then applied for 2 min during the on-going  $STA_2$ -induced contraction. The concentration of bradykinin used was 0.1  $\mu$ M so as to obtain a reproducible endothelium-dependent relaxation, as reported previously (Suzuki *et al.* 2000).

To examine the concentration-dependent effects of the stable prostacyclin analogue, beraprost, on the  $STA_2$ -induced contraction, endothelium-intact strips from both groups of women were treated with L-NNA (0.3 mM) plus diclofenac (3  $\mu$ M). The preparations were first contracted with  $STA<sub>2</sub>$  and, after a steadystate contraction had been attained, beraprost (0.1–10 nM) was then cumulatively applied for 2 min at each concentration from low to high concentration during the on-going  $STA<sub>2</sub>$  -induced contraction.

### **Recording of membrane potential changes**

The membrane potential was measured using a conventional microelectrode technique, as described previously (Yamashita *et al*. 1999; Ohashi *et al*. 2000). To enable recording of membrane potentials, an endothelium-intact strip was placed in a chamber of 0.7 ml volume, pinned down to the bottom of the chamber and superfused with warmed (36–37 °C) Krebs solution at a flow rate of about 2 ml min<sup>-1</sup>. Glass microelectrodes were made from borosilicate glass tubing (o.d., 1.2 mm with a glass filament inside; Hilgenberg, Malsfeld, Germany), then filled with 1 M KCl. The resistance of the electrodes was 80–180 M $\Omega$ . The electrode was inserted into smooth muscle cells from the luminal side using a micromanipulator (model MHW-3; Narishige International, Tokyo, Japan). Membrane potentials recorded using an Axoclamp-2B amplifier (Axon Instruments, Foster City, CA, USA) were displayed on a cathode-ray oscilloscope (model VC-6020; Hitachi, Tokyo, Japan) and data were stored at an acquisition rate of 100 Hz using an Axoscope 7.0/Digidata 1200 data acquisition system (Axon Instruments) on an IBM/AT-compatible PC.

To examine its effect on the smooth muscle cell membrane potential, bradykinin  $(0.1 \mu M)$  was applied for 1.5 min to endothelium-intact strips treated with L-NNA (both groups of women). The effects of diclofenac with or without charybdotoxin (CTX, a blocker of intermediate- and large-conductance  $Ca^{2+}$ activated  $K^+$  channels) plus apamin (a blocker of small-conductance Ca2+-activated K+ channels; Garland *et al*. 1995; Marchenko & Sage, 1996) on the bradykinin-induced hyperpolarization were examined as follows. In endothelium-intact, L-NNA-treated strips, bradykinin was applied for 1.5 min (to record the control response) followed by a 30 min washout (to allow the response to recover). Diclofenac (3  $\mu$ M) was then applied for 60 min and bradykinin was again applied in the presence of diclofenac. Finally, after a 30 min washout with a solution containing diclofenac, CTX (0.1  $\mu$ M) plus apamin (0.1  $\mu$ M) were applied for 15 min and bradykinin was then applied in the presence of CTX plus apamin. The concentration of CTX and apamin was 0.1  $\mu$ M, so as to obtain their selective actions (Garland *et al*. 1995; Marchenko & Sage, 1996). This series was performed in one and the same strip.

To observe its effect on the smooth muscle cell membrane potential, beraprost (10 nM) was applied for 1.5 min in endothelium-intact strips treated with diclofenac plus L-NNA (both groups of women).

#### Assay for 6-keto-PGF<sub>1 $\alpha$ </sub>

After equilibration for 2 h in Krebs solution, endothelium-intact strips were transferred to 0.4 ml Krebs solution containing L-NNA



Data are expressed as means  $\pm$  s.E.M. \*Significant *vs*. normotensive pregnant at  $P < 0.05$  by Student's unpaired t test with  $F$  test.

(0.3 mM) plus guanethidine (5  $\mu$ M) and equilibrated for 90 min at 36 °C. Bradykinin (final concentration, 0.1  $\mu$ M) was then added to the tube for 5 min. For the assay, a 50  $\mu$ l sample of the solution was taken from the tube, and the concentration of 6-keto-PGF<sub>1a</sub>-like immunoreactivity was measured using an enzyme immunoassay kit purchased from Amersham Pharmacia Biotech (Tokyo, Japan). The assay protocol for this followed a manual supplied by Amersham Pharmacia Biotech (Yamashita *et al*. 1999). The strips were homogenized, then centrifuged and the pellets were entered into a protein assay performed using a modified Lowry method (DC protein Assay kit; Bio-Rad, Hercules, CA, USA). The content of 6-keto-PGF<sub>1a</sub>-like immunoreactivity is expressed per milligram protein for measurements made over a 5 min period with or without bradykinin.

#### **Solutions**

The ionic composition of the Krebs solution was as follows (mM):  $\rm Na^+$ , 137.4;  $\rm K^+$ , 5.9;  $\rm Mg^{2+}$ , 1.2;  $\rm Ca^{2+}$ , 2.6;  $\rm HCO_3^-$ , 15.5;  $\rm H_2PO_4^-$ , 1.2; Cl<sup>-</sup>, 134; and glucose, 11.5. The Krebs solution contained guanethidine (5  $\mu$ M, to prevent noradrenaline outflow from sympathetic nerves) and L-NNA (to prevent the release of NO from the endothelium). High-K<sup>+</sup> solution (80 mM) was prepared by replacing sodium chloride with potassium chloride isosmotically. The solutions were bubbled with 95 % oxygen and 5 % carbon dioxide and the pH values were adjusted to 7.3–7.4 using NaOH and HCl.

#### **Drugs**

The drugs used were as follows: bradykinin (Peptide Institute Inc., Osaka, Japan), L-NNA and diclofenac sodium (Sigma Chemical Co., St Louis, MO, USA) and guanethidine (Tokyo Kasei, Tokyo, Japan). Beraprost sodium was kindly provided by Yamanouchi Pharmaceutical (Tokyo, Japan) and  $STA<sub>2</sub>$  by Ono Pharmaceutical (Osaka, Japan). L-NNA was directly diluted in Krebs solution (0.3 mM). STA<sub>2</sub> was diluted in absolute ethanol to make a 10 mM stock solution and stored at  $-80^{\circ}$ C until use. The other agents were dissolved in ultra-pure MilliQ water (Milli-Q SP/Milli RX system; Japan Millipore Corp., Tokyo, Japan).

#### **Statistical analysis**

All data are expressed as means ± S.E.M., with the *n* values representing the number of subjects. The concentration–response curve for the relaxation induced by beraprost on the  $STA_2$ induced contraction was obtained by fitting the data points for each strip by a nonlinear least-squares method using commercial

Table 2. Effect of diclofenac on mechanical responses

			STA <sub>2</sub> -induced tension	BK-induced relaxation						
		Maximum $(kN m^{-2})$		Maximum (%)		Duration $(s)$				
	n	STA,	$STA, +DF$	BK.	$BK+DF$	BK	$BK+DF$			
Normotensive pregnant		$61.5 \pm 3.4$	$85.0 \pm 7.5*$	$81.5 \pm 2.9$	$55.9 \pm 3.4*$	$348 \pm 12$	$221 \pm 26*$			
Pre-eclampsia	4	$57.5 \pm 5.4$	$66.8 \pm 9.1$	$64.5 \pm 2.0$ †	$57.7 \pm 3.5$	$189 \pm 10^{+1}$	$174 \pm 30$			
Data are expressed as means $\pm$ s.E.M. STA <sub>2</sub> was applied to endothelium-intact strips treated with the NO synthase inhibitor, L-NNA. The concentration of the thromboxane A, mimetic, $STA_2$ , was 3 nM for normotensive pregnant women and 1 nm for pre-eclamptic women. Bradykinin (BK, 0.1 $\mu$ M) was applied for 2 min during the STA <sub>2</sub> -induced contraction. After recording the control response, the										
strip was pretreated with cyclooxygenase inhibitor, diclofenac (DF, $3 \mu M$ ), for 60 min, which was then										
present throughout the experiment. *Significant at $P < 0.05$ vs. before application of diclofenac.										



 $\dagger P$  < 0.05 *vs.* normotensive pregnant women.

#### **Figure 1. Effect of diclofenac on bradykinin-induced relaxation**

*A*, original traces of the relaxation induced by bradykinin (0.1  $\mu$ M) of the contraction induced by the stable thromboxane  $A_2$  mimetic, STA2, in endothelium-intact strips from a normotensive pregnant woman (*a*) and from a pre-eclamptic woman (*b*). Bradykinin was applied for 2 min as indicated by the bars. After recording the control response (Diclofenac $(-)$ ), the strip was pretreated for 60 min with the cyclooxygenase inhibitor, diclofenac.  $STA_2$  was then applied in the presence of diclofenac (Diclofenac  $(+)$ ) and bradykinin was applied. *B*, summary of the effect of diclofenac on the bradykinin-induced relaxation before  $(\square)$  and after an application of diclofenac ( $\blacksquare$ ). Results are shown as means  $\pm$  s.e.m. \* *P* < 0.05 *vs*. before application of diclofenac (Student's paired *t* test with an *F* test). † *P* < 0.05 *vs*. normotensive pregnant women (Student's unpaired *t* test with *F* test).

software (Kaleida graph; Synergy Software, PA, USA). A two-way repeated-measures ANOVA followed by Scheffé's *post hoc F* test were used for the statistical analysis, or Student's paired and unpaired *t*tests with an *F* test were used. Probabilities less than 5 % (*P* < 0.05) were considered significant.

## **RESULTS**

## **Effects of diclofenac on STA2-induced contraction**

 $STA<sub>2</sub>$  produced a contraction with oscillations in endothelium-intact strips from both groups of women (Fig. 1*A*). The magnitude of the force induced by 3 nm  $STA<sub>2</sub>$ for normotensive pregnant women was not significantly different from that induced by 1 nm  $STA<sub>2</sub>$  for pre-eclamptic women  $(P = 0.7349;$  Table 2). Diclofenac attenuated the oscillations and enhanced the contraction induced by  $STA<sub>2</sub>$ in strips from normotensive pregnant women ( $P = 0.015$ ; Table 2 and Fig. 1*A*). By contrast, in strips from preeclamptic women, this agent attenuated the oscillations but did not modify the contraction induced by  $STA<sub>2</sub>$ (*P* = 0.349; Table 2 and Fig. 1*B*).

In endothelium-denuded strips,  $STA<sub>2</sub>$  (1 nm) induced a contraction with no oscillations for both groups of women (not shown). In absolute terms, the magnitude of the  $STA<sub>2</sub>$ -induced tension in endothelium-denuded strips was almost the same as that seen in endothelium-intact strips treated with L-NNA plus diclofenac. In endotheliumdenuded strips, the value obtained in the presence of 3 nM STA<sub>2</sub> for normotensive pregnant women was  $100.6 \pm$ 10.6 kN m<sup>-2</sup> ( $n = 4$ ,  $P = 0.215$  *vs.* endothelium-intact strips treated with L-NNA + diclofenac) and that for pre-eclamptic women in the presence of 1 nm  $STA_2$  was  $90.5 \pm 15.3$  kN m<sup>-2</sup>  $(n = 4, P = 0.175)$ . Under our conditions, diclofenac had no effect on the  $STA_2$ -induced contraction in endotheliumdenuded strips from either group of women (*P* > 0.15 in each case,  $n = 4$ ).

## **Effects of diclofenac on bradykinin-induced relaxation**

Bradykinin (0.1  $\mu$ M) produced a relaxation of the contraction induced by  $STA<sub>2</sub>$  in strips from both normotensive



	Normotensive $pregnant$ (mV)	Pre-eclampsia (mV)	
I. Resting membrane potential			
Control	$-59.9 \pm 1.3(9)$	$-56.0 \pm 1.1(6)$	
$+DF$	$-55.1 \pm 0.8 \pm (9)$	$-53.2 \pm 1.2$ (6)	
$+DF + CTX + a$ pamin	$-51.8 \pm 0.4 \pm (4)$	$-49.4 \pm 0.7 \pm (4)$	
II. Bradykinin-induced hyperpolarization			
Control			
initial hyperpolarization	$-12.4 \pm 1.4$ (6)	$-11.3 \pm 1.2(6)$	
second hyperpolarization	$-4.3 \pm 0.7$ (6)	$-2.6 \pm 0.4^{\ast}$ (6)	
$+DF$			
initial hyperpolarization	$-11.5 \pm 1.8$ (6)	$-16.4 \pm 1.0$ (4)	
second hyperpolarization	$-0.4 \pm 0.6 \pm (6)$	$-0.4 \pm 1.6(4)$	
$+DF + CTX + a$			
initial hyperpolarization	$-0.6 \pm 0.6 \pm (4)$	$-1.2 \pm 1.2 \pm (3)$	

Table 3. Effect of diclofenac with and without CTX + apamin on bradykinin-induced hyperpolarization

Data are expressed as means  $\pm$  s.E.M. The number of women is given in parentheses. The initial hyperpolarization was calculated as the maximum hyperpolarization obtained within a 3 min period after application of bradykinin, and the second hyperpolarization was calculated as the maximum hyperpolarization obtained within a 5-17 min period after washout of bradykinin. The cyclooxygenase inhibitor, diclofenac (DF, 3  $\mu$ M), was given as pretreatment for 60 min and was present throughout the experiment. Charybdotoxin (CTX) + apamin (Ca<sup>2+</sup>-activated K<sup>+</sup> channel inhibitors) were given as pretreatment for 15 min in the presence of diclofenac and were present thereafter.  $*P < 0.05$  vs. normotensive pregnant women.  $\frac{1}{7}P < 0.05$  vs. before application of diclofenac.  $\frac{1}{7}P < 0.05$  vs. before application of  $CTX + a$ pamin.

pregnant (Fig. 1*Aa*) and pre-eclamptic women (Fig. 1*Ab*). Bradykinin did not produce a relaxation (rather, it produced a contraction) in endothelium-denuded strips from either group ( $n = 4$ , data not shown). Both the magnitude and the duration of the bradykinin-induced relaxation were significantly smaller for pre-eclamptic women than for normotensive pregnant women (for the magnitude,  $P = 0.002$ ) and for the duration, *P* < 0.001; Table 2). Diclofenac  $(3 \mu)$  significantly attenuated both the magnitude and the duration of the relaxation induced by bradykinin in normotensive pregnant women (for the magnitude,  $P < 0.001$  and for the duration,  $P = 0.001$ ). By contrast, in strips from pre-eclamptic women, diclofenac modified neither the magnitude nor the duration of the relaxation induced by bradykinin (for the magnitude, *P* = 0.098 and for the duration,  $P = 0.604$ ). The bradykinin-induced relaxation observed in the presence of diclofenac was not significantly different between the two groups (for the magnitude,  $P = 0.717$  and for the duration,  $P = 0.243$ ; Fig. 1*B* and Table 2).

## **Effect of bradykinin on membrane potential**

The resting membrane potential of smooth muscle cells in endothelium-intact strips was  $-59.9 \pm 1.3$  mV for normotensive pregnant women  $(n = 9)$  and  $-56.0 \pm 1.1$  mV for pre-eclamptic women  $(n = 6)$ , and these values were not significantly different from each other ( $P = 0.053$ ). Under our conditions, bradykinin  $(0.1 \mu M)$  produced an initial,





Original traces of the effect of bradykinin on membrane potential in smooth muscle cells of endothelium-intact omental resistance arteries from a normotensive pregnant woman (*A*) and a preeclamptic woman  $(B)$ . Bradykinin  $(0.1 \mu M)$  was applied for 1.5 min as indicated by the bar. All experiments were carried out in the presence of the NO synthase inhibitor, L-NNA (0.3 mM), and guanethidine (5  $\mu$ M, to prevent noradrenaline outflow from sympathetic nerves), both of which were applied as pretreatments for 90 min before the start of the experiment. Dashed lines indicate the resting membrane potential level in the presence of L-NNA + guanethidine.

followed by a second phase of membrane hyperpolarization in both groups of women. The initial phase was not significantly different between the two groups  $(P = 0.5936)$ , but the second phase was significantly smaller for pre-eclamptic women than that for normotensive pregnant women ( $P = 0.041$ ; Fig. 2 and Table 3).

Diclofenac slightly depolarized the membrane for normotensive pregnant women ( $P = 0.035$ ) but had no effect for pre-eclamptic women  $(P = 0.097;$  Table 3). Figure 3 shows the effect of diclofenac on the bradykinin-induced hyperpolarization in endothelium-intact strips from normotensive pregnant women. Diclofenac had no effect on the bradykinin-induced initial phase of hyperpolarization for either group of women (for normotensive pregnant women,  $P = 0.5936$  and for pre-eclamptic women,  $P = 0.054$ ) and it significantly inhibited the second phase of the hyperpolarization for normotensive pregnant women only







#### **Figure 3. Effect of diclofenac without and with charybdotoxin + apamin on bradykinin-induced hyperpolarization in an endothelium-intact strip from a normotensive pregnant woman**

*A*, original trace of the effect of bradykinin (0.1  $\mu$ M) on membrane potential in smooth muscle cells of an endothelium-intact strip from a normotensive pregnant woman (Control). *B*, effect of the cyclooxygenase inhibitor, diclofenac (DF). After recording the control response (shown in *A*), the strip was pretreated with DF  $(3 \mu M)$  and bradykinin was applied in the presence of DF. *C*, effect of the Ca<sup>2+</sup>-activated K<sup>+</sup> channel inhibitors, charybdotoxin (CTX) + apamin, in the presence of diclofenac. In the presence of diclofenac, the strip was pre-treated for 15 min with CTX  $(0.1 \mu M)$  + apamin  $(0.1 \mu M)$  and bradykinin was applied in the presence of  $DF + CTX +$  apamin.

 $(P < 0.01$ ; Table 3). In the presence of diclofenac, charybdotoxin (CTX, 0.1  $\mu$ M) plus apamin (0.1  $\mu$ M) depolarized the membrane (for normotensive pregnant women,  $P = 0.003$  and for pre-eclamptic women,  $P = 0.003$ ) and greatly attenuated the bradykinin-induced initial hyperpolarization  $(P < 0.001$  in each case; Table 3).

## **Effect of beraprost on electrical and mechanical activities**

In endothelium-intact strips treated with L-NNA (0.3 mM) plus diclofenac (3  $\mu$ M), beraprost (0.1–10 nM) produced a concentration-dependent relaxation of the contraction induced by  $STA<sub>2</sub>$  in both groups of women. The relaxation response to beraprost was not significantly different between the two groups (by a two-way repeated-measures  $ANOVA, P = 0.996; Fig. 4$ .

In endothelium-intact strips treated with L-NNA (0.3 mM) plus diclofenac  $(3 \mu M)$ , beraprost  $(10 \text{ nm})$  produced a hyperpolarization in both groups of women. The hyperpolarization was by  $-12.8 \pm 2.2$  mV for normotensive pregnant women ( $n = 5$ ) and by  $-11.7 \pm 1.3$  mV for preeclamptic women  $(n = 4)$ , and these values were not significantly different  $(P = 0.645)$ .

## **Effect of bradykinin on prostacyclin synthesis**

In endothelium-intact strips treated with L-NNA (0.3 mM), the basal concentration of 6-keto-PGF<sub>1 $\alpha$ </sub> was significantly lower for pre-eclamptic women  $(0.45 \pm 0.15 \text{ ng (mg protein)}^{-1})$  $(5 \text{ min})^{-1}$ ,  $n = 8$ ) than for normotensive pregnant women  $(1.39 \pm 0.27 \text{ ng (mg protein)}^{-1} (5 \text{ min})^{-1}, n = 12, P = 0.007;$ Fig. 5). Bradykinin  $(0.1 \mu M)$  significantly increased the



**Figure 4. Effect of beraprost on STA2-induced contraction**

A concentration-dependent relaxation in response to a stable analogue of prostacyclin, beraprost (0.1-10 nM), was obtained during the on-going  $STA<sub>2</sub>$ -induced contraction in endotheliumintact strips treated with L-NNA + diclofenac from normotensive pregnant women  $(0, n = 6)$  and from pre-eclamptic women  $(\bullet, n = 5)$ . Results are shown as means  $\pm$  s.e.m.

concentration of 6-keto-PGF<sub>1 $\alpha$ </sub> in both groups of women but the concentration recorded in the presence of bradykinin was significantly lower for pre-eclamptic women  $(3.54 \pm 0.92 \text{ ng (mg protein)}^{-1} (5 \text{ min})^{-1}, n = 5)$ than for normotensive pregnant women (19.78  $\pm$  1.81 ng  $(mg protein)^{-1} (5 min)^{-1}, n = 4, P < 0.001$ ; Fig. 5).

## **DISCUSSION**

Pregnancy is associated with profound physiological alterations in vascular behaviour, including a marked vasodilatation and a refractoriness to vasopressor responses (Friedman, 1988). The vascular adaptations to pregnancy are thought to depend to a large extent on an increase in the function of endothelium-derived vasorelaxing substances, such as prostacyclin, NO and EDHF (Friedman, 1988; Knock & Poston, 1996; Sladek *et al*. 1997; Pascoal *et al*. 1998; Suzuki *et al*. 2000). Pre-eclampsia is a human pregnancy-specific syndrome that is characterized by a marked increase in peripheral vascular resistance with an abnormality in the role played by endothelium-derived vasorelaxing substances, especially NO (Lenfant *et al*. 1990; Poston *et al*. 1995; Sladek *et al*. 1997; Suzuki *et al*. 2000).

## **Change in the role played by spontaneously released PGs in pre-eclampsia**

It has been found that, in the blood of pre-eclamptic women, the lipid peroxides that inhibit prostacyclin synthase are abnormally increased, while the concentration of 6-keto- $PGF_{1\alpha}$  (a stable metabolite of prostacyclin) is significantly reduced (Whorton *et al*. 1985; Wang *et al*. 1992). In the present experiments, in endothelium-intact omental resistance arteries treated with the NO synthase inhibitor, L-NNA, cyclooxygenase inhibition by diclofenac significantly enhanced the contraction induced by a stable analogue of thromboxane  $A_2$  (STA<sub>2</sub>) for normotensive pregnant women but not for pre-eclamptic women. This action of diclofenac was not seen in endothelium-denuded strips. Furthermore, diclofenac depolarized the membrane of smooth muscle cells in endothelium-intact strips for normotensive pregnant women but not for pre-eclamptic women. Moreover, in endothelium-intact strips, the basal concentration of 6-keto-PGF<sub>1 $\alpha$ </sub> was significantly lower for pre-eclamptic women than for normotensive pregnant women although the stable prostacyclin analogue, beraprost, at a low concentration (10 nM), produced a hyperpolarization of the same magnitude in the smooth muscle cells from both groups of women. These results suggest that the role played by spontaneously released prostacyclin from the endothelium may be reduced in resistance arteries in preeclampsia (by comparison with the situation in normotensive pregnant women).

## **Change in the role played by PGs in the presence of bradykinin in pre-eclampsia**

It has been found that, in addition to EDHF, endotheliumderived PGs also hyperpolarize the membrane in vascular preparations from some animals and humans (Nishiyama *et al*. 1998; Yamashita *et al*. 1999; Coleman *et al*. 2001). In the present experiments, we found that, in endotheliumintact human omental resistance arteries, bradykinin produced an initial, followed by a second phase of membrane hyperpolarization in smooth muscle cells from both normotensive pregnant and pre-eclamptic women. Since these strips were treated with L-NNA, the role of endothelium-derived NO in these hyperpolarizations can be ruled out. Diclofenac inhibited the second phase (but not the initial phase) of the hyperpolarization, and the initial phase remaining in the presence of diclofenac was blocked by a combined application of CTX (a blocker of intermediate- and large-conductance  $Ca^{2+}$ -activated  $K^+$ channels) plus apamin (a blocker of small-conductance Ca2+-activated K+ channels; Garland *et al*. 1995; Marchenko & Sage, 1996). These results suggest that, in human omental resistance arteries, the bradykinin-induced initial hyperpolarization is due to an action of EDHF while the second phase is mediated by the action of PGs. Most importantly, we found that, in endothelium-intact strips treated with L-NNA, the bradykinin-induced PGs-mediated hyperpolarization (but not the EDHF-mediated one) was significantly smaller for pre-eclamptic women than for normotensive pregnant women. Furthermore, under our conditions, diclofenac inhibited the bradykinin-induced relaxation only for normotensive pregnant women. Taken



## **Figure 5. Effect of bradykinin on the synthesis of prostacyclin**

Bradykinin (0.1  $\mu$ M) was applied for 5 min in endothelium-intact strips treated with L-NNA from normotensive pregnant and preeclamptic women. Data show the concentration of a stable metabolite of prostacyclin, 6-keto-PGF<sub>1a</sub>, in the absence ( $\square$ ) and presence of bradykinin ( $\blacksquare$ ). Results are shown as means  $\pm$  s.e.m. \* *P* < 0.05 *vs*. in the absence of bradykinin (Student's unpaired *t* test with an *F* test). † *P* < 0.05 *vs*. normotensive pregnant women (Student's unpaired *t* test with an *F* test).

together, these results suggest that the functional role played by endothelium-derived PGs is reduced in omental resistance arteries in pre-eclampsia.

Although bradykinin significantly increased the concentration of 6-keto-PGF<sub>1a</sub> in endothelium-intact omental arteries treated with L-NNA from both groups of women, the concentrations of this metabolite recorded in the absence and presence of bradykinin were significantly smaller for pre-eclamptic women than for normotensive pregnant women. However, in endothelium-intact strips treated with L-NNA plus diclofenac, both the relaxation of the  $STA<sub>2</sub>$ -induced contraction and the hyperpolarization in response to beraprost (a stable analogue of prostacyclin, 10 nM) were identical between the two groups, indicating that the action of prostacyclin on smooth muscle is not modified in pre-eclampsia. Although, so far, there is no available supporting evidence in pregnant human resistance arteries, these results suggest that a reduction in the synthesis of prostacyclin in the endothelium could be responsible for the reduced endothelium-dependent, PGsmediated relaxation seen in omental resistance arteries in pre-eclampsia. However, since vessel function may vary among vascular beds, the overall significance of the present findings will remain uncertain until vessels from other resistance arteries (such as uterine arteries) have been evaluated. On this point, it should be noted that in arteries of subcutaneous fat, the bradykinin-induced prostanoids-dependent relaxation is apparently not modified in pre-eclampsia (compared with the response in normotensive pregnant women; Knock & Poston, 1996). We do not know the reason for the discrepancy but it may, in part, be due to the use of different resistance arteries (omental arteries *vs.* subcutaneous fat arteries) and/or different vasospasmogenic agents (STA<sub>2</sub> *vs*. noradrenaline). This remains to be clarified in future work.

#### **Role played by EDHF in pre-eclampsia**

The accumulated evidence supports the hypothesis that EDHF may play an important role in agonist-stimulated, endothelium-dependent relaxation in pregnant human resistance arteries (Knock & Poston, 1996; Pascoal *et al*. 1998; Suzuki *et al*. 2000).

It was recently found that, in human omental resistance arteries, bradykinin produces an endothelium-dependent relaxation through an action of NO- and PGs-independent factors (Pascoal *et al*. 1998). Since the action of these factors was blocked by CTX plus apamin, it was suggested that this endothelium-dependent relaxation is mediated by an action of EDHF (Suzuki *et al*. 2000), although there was no direct proof for bradykinin-induced membrane hyperpolarization in human pregnant resistance arteries. Furthermore, and more importantly, these authors suggested that the function of EDHF may not be modified in preeclampsia (as compared with the response in normotensive pregnant women; Pascoal *et al*. 1998; Suzuki *et al*. 2000). In the present experiments, we demonstrated that, in pregnant human omental resistance arteries, bradykinin does indeed produce a smooth muscle cell membrane hyperpolarization which is sensitive to CTX plus apamin, and is thus a supposed action of EDHF. Most importantly, the magnitude of the hyperpolarization mediated by EDHF in omental resistance arteries in pre-eclampsia is similar to the response seen in normotensive pregnant women. Thus, in accord with the previous notion, it is suggested that the function of EDHF remains normal in these human resistance arteries in pre-eclampsia. It is known that an increase in the intracellular concentration of  $Ca^{2+} ([Ca^{2+}]_i)$  in endothelial cells plays a crucial role in mediating agonist-induced responses, such as those induced not only by EDHF but also by PGs in smooth muscle cells (Kuriyama *et al.* 1998). We found that the synthesis of PGs induced by bradykinin (but not the EDHF response) is reduced in omental resistance arteries in preeclampsia (compared with that in normotensive pregnant women). Taken together, these pieces of evidence suggest that the reduced synthesis of PGs seen in pre-eclamptic women may not be due simply to a reduction in the bradykinin-induced increase in  $[Ca^{2+}]$ ; in endothelial cells. The underlying mechanism still needs to be clarified in future work. Furthermore, the present results suggest that, in pre-eclamptic women, caution should be used in the employment of a cyclooxygenase inhibitor (especially at high concentrations) under conditions in which visceral blood flow needs to be kept constant.

In conclusion, in human omental resistance arteries, the synthesis of prostacyclin in endothelial cells is reduced in pre-eclampsia and thus the relaxation mediated by endothelium-derived PGs in the presence of bradykinin is down-regulated. When taken together with our previous findings (Suzuki *et al*. 2000), this suggests that in preeclampsia, the function not only of NO but also of PGs in endothelium-dependent relaxation is down-regulated, while the function of EDHF remains normal.

## **REFERENCES**

- CINES, D. B., POLLAK, E. S., BUCK, C. A., LOSCALZO, J., ZIMMERMAN, G. A., MCEVER, R. P., POBER, J. S., WICK, T. M., KONKLE, B. A., SCHWARTZ, B. S., BARNATHAN, E. S., MCCRAE, K. R., HUG, B. A., SCHMIDT, A. M. & STERN, D. M. (1998). Endothelial cells in physiology and in the pathophysiology of vascular disorders. *Blood* **91**, 3527–3561.
- COLEMAN, H. A., TARE, M. & PARKINGTON, H. C. (2001). K+ currents underlying the action of endothelium-derived hyperpolarizing factor in guinea-pig, rat and human blood vessels. *Journal of Physiology* **531**, 359–373.
- CUNNINGHAM, F. G. (2001). Hypertensive disorders in pregnancy. In *Williams Obstetrics*, ed. CUNNINGHAM, F. G., GANT, N. F., GILSTRAP, L. C. III, HAUTH, J. C. & WENSTROM, K. D., pp. 567–618. McGraw-Hill, New York.
- FITZGERALD, D. J., ENTMAN, S. S., MULLOY, K. & FITZGERALD, G. A. (1987). Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. *Circulation* **75**, 956–963.
- FRIEDMAN, S. A. (1988). Preeclampsia: a review of the prostaglandins. *Obstetrics and Gynecology* **71**, 122–137.
- GARLAND, C. J., PLANE, F., KEMP, B. K. & COCKS, T. M. (1995). Endothelium-dependent hyperpolarization: a role in the control of vascular tone. *Trends in Pharmacological Sciences* **16**, 23–30.
- GOODMAN, R. P., KILLAM, A. P., BRASH, A. R. & BRANCH, R. A. (1982). Prostacyclin production during pregnancy: comparison of production during normal pregnancy and pregnancy complicated by hypertension. *American Journal of Obstetrics and Gynecology* **142**, 817–822.
- ITOH, T., KAJIKURI, J. & KURIYAMA, H. (1992). Characteristic features of noradrenaline-induced  $Ca^{2+}$  mobilization and tension in arterial smooth muscle of the rabbit. *Journal of Physiology* **457**, 297–314.
- KAKUYAMA, M., VALLANCE, P. & AHLUWALIA, A. (1998). Endotheliumdependent sensory NANC vasodilatation: involvement of ATP, CGRP and a possible NO store. *British Journal of Pharmacology* **123**, 310–316.
- KANMURA, Y., ITOH, T. & KURIYAMA, H. (1987). Mechanisms of vasoconstriction induced by 9,11,epithio-11,12-methanothromboxane A<sub>2</sub> in the rabbit coronary artery. *Circulation Research* **60**, 402–409.
- KNOCK, G. A. & POSTON, L. (1996). Bradykinin-mediated relaxation of isolated maternal resistance arteries in normal pregnancy and preeclampsia. *American Journal of Obstetrics and Gynecology* **175**, 1668–1674.
- KURIYAMA, H., KITAMURA, K., ITOH, T. & INOUE, R. (1998). Physiological features of visceral smooth muscle cells, with special reference to receptors and ion channels. *Physiological Reviews* **78**, 811–920.
- LENFANT, C., GIFFORD, R. W. JR & ZUSPAN, F. P. (1990). National high blood pressure education program working group report on high blood pressure in pregnancy. *American Journal of Obstetrics and Gynecology* **163**, 1691–1712.
- MARCHENKO, S. M. & SAGE, S. O. (1996). Calcium-activated potassium channels in the endothelium of intact rat aorta. *Journal of Physiology* **492**, 53–60.
- MISHIMA, S., MIYAHARA, H. & SUZUKI, H. (1984). Transmitter release modulated by  $\alpha$ -adrenoceptor antagonists in the rabbit mesenteric artery: a comparison between noradrenaline outflow and electrical activity. *British Journal of Pharmacology* **83**, 537–547.
- MONCADA, S., GRYGLEWSKI, R., BUNTING, S. & VANE, J. R. (1976). An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. *Nature* **263**, 663–665.
- MONCADA, S., PALMER, R. M. & HIGGS, E. A. (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. *Pharmacological Reviews* **43**, 109–142.
- NISHIYAMA, M., HASHITANI, H., FUKUTA, H., YAMAMOTO, Y. & SUZUKI, H. (1998). Potassium channels activated in the endotheliumdependent hyperpolarization in guinea-pig coronary artery. *Journal of Physiology* **510**, 455–465.
- OHASHI, M., DOHI, Y. & ITOH, T. (2000). Possible mechanisms underlying the vasodilatation induced by olprinone, phosphodiesterase III inhibitor, in rabbit coronary artery. *British Journal of Pharmacology* **129**, 1000–1006.
- PASCOAL, I. F., LINDHEIMER, M. D., NALBANTIAN-BRANDT, C. & UMANS, J. G. (1998). Preeclampsia selectively impairs endotheliumdependent relaxation and leads to oscillatory activity in small omental arteries. *Journal of Clinical Investigation* **101**, 464–470.
- POSTON, L., MCCARTHY, A. L. & RITTER, J. M. (1995). Control of vascular resistance in the maternal and feto-placental arterial beds. *Pharmacology and Therapeutics* **65**, 215–239.
- REMUZZI, G., MISIANI, R., MURATORE, D., MARCHESI, D., LIVIO, M., SCHIEPPATI, A., MECCA, G., DE GAETANO, G. & DONATI, M. B. (1979). Prostacyclin and human fetal circulation. *Prostaglandins* **18**, 341–347.
- SLADEK, S. M., MAGNESS, R. R. & CONRAD, K. P. (1997). Nitric oxide and pregnancy. *American Journal of Physiology* **272**, R441–463.
- SUZUKI, S., KAJIKURI, J. & ITOH, T. (1991). Effects of endothelin-1 on endothelial cells in the porcine coronary artery. *Circulation Research* **69**, 1361–1368.
- SUZUKI, Y., KAJIKURI, J., SUZUMORI, K. & ITOH, T. (2000). Mechanisms underlying the reduced endothelium-dependent relaxation in human omental resistance arteries in pre-eclampsia. *Journal of Physiology* **527**, 163–174.
- VALLANCE, P., COLLIER, J. & MONCADA, S. (1989). Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. *Lancet* **336**, 997–1000.
- WALSH, S. W. (1985). Preeclampsia: an imbalance in placental prostacyclin and thromboxane production. *American Journal of Obstetrics and Gynecology* **152**, 235–240.
- WANG, Y., WALSH, S. W. & KAY, H. H. (1992). Placental lipid peroxidase and thromboxane are increased and prostacyclin is decreased in women with preeclampsia. *American Journal of Obstetrics and Gynecology* **167**, 946–949.
- WHORTON, A. R., MONTOGOMERY, M. E. & KENT, R. S. (1985). Effect of hydrogen peroxide on prostaglandin production and cellular integrity in cultured porcine aortic endothelial cells. *Journal of Clinical Investigation* **76**, 295–302.
- YAMAKAWA, N., OHHASHI, M., WAGA, S. & ITOH, T. (1997). Role of endothelium in regulation of smooth muscle membrane potential and tone in the rabbit middle cerebral artery. *British Journal of Pharmacology* **121**, 1315–1322.
- YAMASHITA, A., KAJIKURI, J., OHASHI, M., KANMURA, Y. & ITOH, T. (1999). Inhibitory effects of propofol on acetylcholine-induced, endothelium-dependent relaxation and prostacyclin synthesis in rabbit mesenteric resistance arteries. *Anesthesiology* **91**, 1080–1089.

### **Acknowledgements**

We thank Dr Robert J. Timms for a critical reading of the manuscript. We also thank Drs K. Teshigawara, S. Kajiura, K. Kojima and T. Wada and the staff of the delivery suites at Nagoya City University Hospital for their cooperation in this study. This work was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan, by a grant from the JAOG Ogyaa Donation Foundation, Tokyo, Japan and by a Grant-in-Aid for Research in Nagoya City University.